- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05130320
Severe Asthma Covid Vaccine Response Study (SHINE)
SHINE: Severe Asthma Covid Vaccine Response Study
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
SARS-CoV-2 and the resulting COVID-19 pandemic has had a major impact on quality of life in people with severe asthma. Careful isolation and lockdown measures have protected many patients, but with major impacts on wellbeing and mental health. Vaccination opens a "light at the end of the tunnel" by protecting against COVID-19. However, the following questions remain unanswered for Covid vaccination in severe asthma: 1) What are patients' expectations/attitudes towards vaccination? 2) Will vaccines induce good immune responses which protect from Covid-19 infections? The first question is being addressed by a survey created SHARP, a European Clinical Research Collaboration on severe asthma- people with asthma from the UK and Europe will be invited to complete the survey. To complement this, the investigators propose a UK pilot study (carried out in up to four severe asthma centres) to measure immune responses following vaccination in 200 people with severe asthma. The investigators will invite 120 people receiving asthma biologics (monoclonal antibodies), 40 people receiving asthma inhalers, 40 people needing daily steroid tablets to control their asthma, and 50 age-matched healthy people. Immune responses will be studied using a simple home blood antibody test posted to participants. By pricking their finger, patients will collect 5-6 drops of blood in a small test tube and will post back on the same day to a laboratory in London. Tests will be done twice: after the first and second vaccine doses.
The study will help us understand if the body's immune response to the COVID-19 vaccine is different in people with severe asthma who are on different treatments to manage their symptoms.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienkontakt
- Name: Thomas Bower
- Telefonnummer: 02381204989
- E-Mail: thomas.bower@uhs.nhs.uk
Studienorte
-
-
-
Exeter, Vereinigtes Königreich, EX2 5DW
- Noch keine Rekrutierung
- Royal Devon and Exeter NHS Foundation Trust
-
Kontakt:
- Lisa Treeby
- Telefonnummer: 01392 403814
- E-Mail: lisa.treeby@nhs.net
-
Kontakt:
- Matthew Masoli
- E-Mail: matthew.masoli@nhs.net
-
Hauptermittler:
- Matthew Masoli
-
Glasgow, Vereinigtes Königreich, G12 0YN
- Rekrutierung
- Gartnavel General Hospital
-
Hauptermittler:
- Rekha Chaudhuri
-
Kontakt:
- Rekha Chaudhuri
- E-Mail: Rekha.Chaudhuri@ggc.scot.nhs.uk
-
Kontakt:
- Kayleigh Mckenna
- E-Mail: Kayleigh.McKenna@ggc.scot.nhs.uk
-
London, Vereinigtes Königreich, SE1 9RT
- Noch keine Rekrutierung
- Guy's and St Thomas' NHS Trust Foundation
-
Kontakt:
- Gill Arbane
- E-Mail: gill.arbane@gstt.nhs.uk
-
Kontakt:
- Mathew Furtado
- E-Mail: Mathew.Furtado@gstt.nhs.uk
-
Hauptermittler:
- David Jackson, MRCP MSc PhD
-
Newcastle, Vereinigtes Königreich, NE1 4LP
- Noch keine Rekrutierung
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
Hauptermittler:
- Simon Doe
-
Kontakt:
- Simon Doe
- E-Mail: simon.doe@nhs.net
-
Kontakt:
- Jamie Brown
- E-Mail: jamie.brown3@nhs.net
-
-
Hampshire
-
Southampton, Hampshire, Vereinigtes Königreich, SO16 6YD
- Rekrutierung
- University Hospital Southampton Nhs Foundation Trust
-
Kontakt:
- Thomas Bower
- Telefonnummer: 02381204989
- E-Mail: thomas.bower@uhs.nhs.uk
-
Hauptermittler:
- Hitasha Rupani
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion criteria:
- Age ≥ 16 years
For asthma patients:
- Diagnosis of severe asthma (based on ATS/ERS consensus criteria)
- Group A: Currently receiving an asthma biologic with treatment having started at least 3 months before first COVID-19 vaccine
- Group B: on maintenance oral steroids at a dose of ≥5mg prednisolone (or equivalent) per day (at the time of first COVID-19 vaccine)
- Group C: not on asthma biologic or maintenance oral steroids (at the time of vaccination) or stopped ≥3 months prior to first COVID-19 vaccine
Exclusion criteria:
- Current pregnancy or planning a pregnancy within the next 6 months
- Current malignancy
- Diagnosis of immunodeficiency requiring treatment
Additional exclusion criteria for asthma patients:
- Group A: maintenance oral steroids at the time of first COVID-19 vaccine
- Group B: on an asthma biologic at the time of first COVID-19 vaccine
Additional exclusion criteria for healthy controls cohort (as assessed by research team):
- No history of asthma or significant other lung disease
- Severe chronic inflammatory disease
- Severe cardiac disease
- Diabetes
- Previous proven COVID-19 infection
- Inability to provide informed consent
- Unwilling to have vaccination
- Participation in another clinical trial involving an investigational medicinal product (IMP).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: Fallkontrolle
- Zeitperspektiven: Interessent
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
Asthma biologics
120 people receiving asthma biologics (monoclonal antibodies)
|
Not Interventional their treatments are their routine NHS care
|
Asthma inhalers
40 people receiving asthma inhalers
|
Not Interventional their treatments are their routine NHS care
|
Steroid tablets
40 people needing daily steroid tablets to control their asthma
|
Not Interventional their treatments are their routine NHS care
|
Healthy Control
50 age-matched healthy people
|
Not Interventional their treatments are their routine NHS care
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Measured immune response
Zeitfenster: 12 Months
|
To compare the measured immune response to vaccination in patients with 200 severe asthma and 50 healthy individuals.
A positive response will be defined as IgG ≥0.201.
|
12 Months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Range of immune responses
Zeitfenster: 12 Months
|
To evaluate the range of immune responses measured by IgG titres (very high: >1.25, high: 0.751-1.25,
medium: 0.401-0.75
or low: 0.201-0.4) in patients with 200 severe asthma and compare this with 50 healthy individuals
|
12 Months
|
Differences in responses between treatment groups
Zeitfenster: 12 Months
|
To identify any differences in responses between patients treated with biologics, standard inhaler treatment with/without maintenance oral corticosteroids (mOCS)
|
12 Months
|
Differences between responses within the three biologics
Zeitfenster: 12 Months
|
To identify any differences between responses to vaccines amongst patient groups treated with three biologics (anti-IgE Omalizumab, anti-IL-5 Mepolizumab, and anti-IL-5receptor Benralizumab)
|
12 Months
|
Mitarbeiter und Ermittler
Mitarbeiter
Ermittler
- Hauptermittler: Hitasha Rupani, University Hospital Southampton Nhs Foundation Trust
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- RHM MED1777
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Coronavirus Antibody Levels
-
Universiteit AntwerpenAbgeschlossenCholesterinspiegel | HDL-Level | LDL-Wert | TG-LevelBelgien
-
Tri-Service General HospitalUnbekanntLow-Level-Lasertherapie
-
Near East University, TurkeyAbgeschlossenLow-Level-LasertherapieZypern
-
Universidade Estadual Paulista Júlio de Mesquita...AbgeschlossenLasertherapie, Low-Level
-
University of Nove de JulhoFundação de Amparo à Pesquisa do Estado de São PauloAbgeschlossenPhototherapie | Systemisch | Low-Level-LasertherapieBrasilien
-
University of Sao PauloAbgeschlossenLeistung | Sport | Low-Level-LasertherapieBrasilien
-
University of Nove de JulhoAbgeschlossenKieferorthopädische Geräte | Low-Level-LichttherapieBrasilien
-
Ting LiUnbekanntNahinfrarotspektroskopie | Low-Level-Licht-/LasertherapieChina
-
University of Sao PauloAbgeschlossenLeistung | Sport | Photobiomodulation | Low-Level-LasertherapieBrasilien
-
Heidelberg UniversityRekrutierung